CA
SUPN icon

Continuum Advisory’s Supernus Pharmaceuticals SUPN Stock Holding History

Continuum Advisory’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$465 Buy
+10
New +$480 ﹤0.01% 1909
2025
Q1 		– Sell
-17
Closed -$615 – 1911
2024
Q4 		$615 Hold
17
– – ﹤0.01% 1703
2024
Q3 		$615 Buy
+17
New +$531 ﹤0.01% 1739

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Continuum Advisory's SUPN Position: Q2 2026 in Review

Continuum Advisory opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 10 shares worth $465. The stake represents ﹤0.01% of the portfolio and ranks #1909 among its holdings. This is a return to the name: Continuum Advisory previously reported a position in SUPN as recently as Q4 2024.

Continuum Advisory first reported a position in SUPN in Q3 2024 and has held it in 3 quarters since. The position peaked at $615 in Q4 2024. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Continuum Advisory held 10 shares of Supernus Pharmaceuticals worth $465 as of Q2 2026.
  • Supernus Pharmaceuticals was a new Continuum Advisory position in Q2 2026.
  • Supernus Pharmaceuticals made up ﹤0.01% of Continuum Advisory's portfolio in Q2 2026, its #1909 holding.
  • Continuum Advisory first reported a position in Supernus Pharmaceuticals in Q3 2024 and has held it in 3 quarters since.
  • Continuum Advisory's Supernus Pharmaceuticals position peaked at $615 in Q4 2024.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Continuum Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.